Grove Collaborative Holdings Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0300 |
| EPS Surprise | 66.67% |
| Revenue estimate | 33.1M |
| Revenue actual | 36.224M |
| Revenue Surprise | 9.44% |
| Release date | Mar 05, 2026 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0500 |
| EPS Surprise | 44.44% |
| Revenue estimate | 42.169M |
| Revenue actual | 42.409M |
| Revenue Surprise | 0.569% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0800 |
| EPS Surprise | 11.11% |
| Revenue estimate | 42.862M |
| Revenue actual | 43.734M |
| Revenue Surprise | 2.03% |
| Release date | Aug 07, 2025 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.100 |
| EPS Surprise | 28.57% |
| Revenue estimate | 44.6M |
| Revenue actual | 44.026M |
| Revenue Surprise | -1.29% |
Last 4 Quarters for Grove Collaborative Holdings
Below you can see how GROV performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $1.29 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.100 |
| EPS surprise | 28.57% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $1.38 |
| Aug 04, 2025 | $1.37 |
| Aug 05, 2025 | $1.34 |
| Aug 06, 2025 | $1.32 |
| Aug 07, 2025 | $1.29 |
| Aug 08, 2025 | $1.39 |
| Aug 11, 2025 | $1.35 |
| Aug 12, 2025 | $1.48 |
| Aug 13, 2025 | $1.47 |
| 4 days before | -6.52% |
| 4 days after | 13.95% |
| On release day | 7.75% |
| Change in period | 6.52% |
| Release date | Nov 13, 2025 |
| Price on release | $1.44 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0800 |
| EPS surprise | 11.11% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $1.37 |
| Nov 10, 2025 | $1.38 |
| Nov 11, 2025 | $1.41 |
| Nov 12, 2025 | $1.43 |
| Nov 13, 2025 | $1.44 |
| Nov 14, 2025 | $1.47 |
| Nov 17, 2025 | $1.34 |
| Nov 18, 2025 | $1.37 |
| Nov 19, 2025 | $1.35 |
| 4 days before | 5.11% |
| 4 days after | -6.25% |
| On release day | 2.08% |
| Change in period | -1.46% |
| Release date | Mar 05, 2026 |
| Price on release | $1.28 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0500 |
| EPS surprise | 44.44% |
| Date | Price |
|---|---|
| Feb 27, 2026 | $1.41 |
| Mar 02, 2026 | $1.40 |
| Mar 03, 2026 | $1.35 |
| Mar 04, 2026 | $1.32 |
| Mar 05, 2026 | $1.28 |
| Mar 06, 2026 | $1.29 |
| Mar 09, 2026 | $1.26 |
| Mar 10, 2026 | $1.28 |
| Mar 11, 2026 | $1.27 |
| 4 days before | -9.22% |
| 4 days after | -0.781% |
| On release day | 0.781% |
| Change in period | -9.93% |
| Release date | May 07, 2026 |
| Price on release | $1.23 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0300 |
| EPS surprise | 66.67% |
| Date | Price |
|---|---|
| May 01, 2026 | $1.16 |
| May 04, 2026 | $1.11 |
| May 05, 2026 | $1.16 |
| May 06, 2026 | $1.21 |
| May 07, 2026 | $1.23 |
| May 08, 2026 | $1.29 |
| May 11, 2026 | $1.30 |
| May 12, 2026 | $1.28 |
| May 13, 2026 | $1.25 |
| 4 days before | 6.03% |
| 4 days after | 1.63% |
| On release day | 4.88% |
| Change in period | 7.76% |
Grove Collaborative Holdings Earnings Call Transcript Summary of Q1 2026
Key points for investors: Grove delivered a better-than-expected Q1 2026 with net revenue of $36.2 million (down 16.8% YoY) and positive adjusted EBITDA of $0.3 million — the second consecutive quarter of positive adjusted EBITDA. Gross margin expanded to 54.8% (+180 bps YoY), driven largely by the new Grove Green Rewards loyalty program which enabled more targeted promotions and reduced broad discounting. Operationally, Grove relaunched a rebuilt mobile app in mid-February, which management says restored customer experience and contributed to improving cohort behavior and repeat order rates. Active customers totaled 553k (−18.5% YoY) and DTC orders were 502k (−19.2% YoY); advertising spend remained disciplined at $1.2 million in Q1 (−58.6% YoY) but management plans a gradual reacceleration as unit economics and CAC improve. Liquidity: cash and equivalents were $10.4 million, operating cash flow was negative $0.7 million (vs. −$6.9M prior year), and availability under the ABL was $1.7 million. Management raised FY26 guidance to net revenue $142.5M–$152.5M (from $140M–$150M) and adjusted EBITDA to breakeven to positive low single-digit millions, reiterating their view that Q1 represents the revenue trough and they expect sequential revenue growth each quarter. Strategic priorities emphasize (1) sustained profitability, (2) balance sheet discipline, (3) reaccelerating revenue via improved customer experience and advertising, and (4) deepening authority in human health (new Chief Medical Adviser, Human Health Advisory Council, physician advisers). Management continues to evaluate strategic options to accelerate scale or unlock shareholder value. Risks remain tied to macro and execution; forward-looking guidance assumes current trade policy.
Sign In
Buy GROV